308 related articles for article (PubMed ID: 27510266)
41. The Dynamic Chromatin Architecture of the Regenerating Liver.
Wang AW; Wang YJ; Zahm AM; Morgan AR; Wangensteen KJ; Kaestner KH
Cell Mol Gastroenterol Hepatol; 2020; 9(1):121-143. PubMed ID: 31629814
[TBL] [Abstract][Full Text] [Related]
42. Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient.
Cao YY; Zhang YL; DU J; Qu YJ; Zhong XM; Bai JL; Song F
Chin Med J (Engl); 2012 Jun; 125(12):2132-6. PubMed ID: 22884142
[TBL] [Abstract][Full Text] [Related]
43. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
[TBL] [Abstract][Full Text] [Related]
44. Efficient Generation of an Fah/Rag2 Dual-Gene Knockout Porcine Cell Line Using CRISPR/Cas9 and Adenovirus.
Gao M; Zhang B; He Y; Yang Q; Deng L; Zhu Y; Lai E; Wang M; Wang L; Yang G; Liao G; Bao J; Bu H
DNA Cell Biol; 2019 Apr; 38(4):314-321. PubMed ID: 30762444
[TBL] [Abstract][Full Text] [Related]
45. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
[TBL] [Abstract][Full Text] [Related]
46. The origin and liver repopulating capacity of murine oval cells.
Wang X; Foster M; Al-Dhalimy M; Lagasse E; Finegold M; Grompe M
Proc Natl Acad Sci U S A; 2003 Sep; 100 Suppl 1(Suppl 1):11881-8. PubMed ID: 12902545
[TBL] [Abstract][Full Text] [Related]
47. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition.
Montini E; Held PK; Noll M; Morcinek N; Al-Dhalimy M; Finegold M; Yant SR; Kay MA; Grompe M
Mol Ther; 2002 Dec; 6(6):759-69. PubMed ID: 12498772
[TBL] [Abstract][Full Text] [Related]
48. No evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients.
Bergeron A; Lettre F; Russo P; Morissette J; Tanguay RM
Gastroenterology; 2004 Nov; 127(5):1381-5. PubMed ID: 15521007
[TBL] [Abstract][Full Text] [Related]
49. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.
Pankowicz FP; Barzi M; Legras X; Hubert L; Mi T; Tomolonis JA; Ravishankar M; Sun Q; Yang D; Borowiak M; Sumazin P; Elsea SH; Bissig-Choisat B; Bissig KD
Nat Commun; 2016 Aug; 7():12642. PubMed ID: 27572891
[TBL] [Abstract][Full Text] [Related]
50. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.
Macias I; Laín A; Bernardo-Seisdedos G; Gil D; Gonzalez E; Falcon-Perez JM; Millet O
J Biol Chem; 2019 Aug; 294(35):13051-13060. PubMed ID: 31300554
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I.
Gil-Martínez J; Macias I; Unione L; Bernardo-Seisdedos G; Lopitz-Otsoa F; Fernandez-Ramos D; Lain A; Sanz-Parra A; Mato JM; Millet O
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670179
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
53. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1.
Bergeron A; D'Astous M; Timm DE; Tanguay RM
J Biol Chem; 2001 May; 276(18):15225-31. PubMed ID: 11278491
[TBL] [Abstract][Full Text] [Related]
54. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I.
Wilber A; Wangensteen KJ; Chen Y; Zhuo L; Frandsen JL; Bell JB; Chen ZJ; Ekker SC; McIvor RS; Wang X
Mol Ther; 2007 Jul; 15(7):1280-7. PubMed ID: 17440442
[TBL] [Abstract][Full Text] [Related]
55. Abnormal social behavior in mice with tyrosinemia type I is associated with an increase of myelin in the cerebral cortex.
Moore ME; Koenig AE; Hillgartner MA; Otap CC; Barnby E; MacGregor GG
Metab Brain Dis; 2017 Dec; 32(6):1829-1841. PubMed ID: 28712060
[TBL] [Abstract][Full Text] [Related]
56. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
[TBL] [Abstract][Full Text] [Related]
57. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
58. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
59. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
[TBL] [Abstract][Full Text] [Related]
60. Animal models reveal pathophysiologies of tyrosinemias.
Endo F; Tanaka Y; Tomoeda K; Tanoue A; Tsujimoto G; Nakamura K
J Nutr; 2003 Jun; 133(6 Suppl 1):2063S-2067S. PubMed ID: 12771366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
